Butobarbital
From Wikipedia, the free encyclopedia
 |
|
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
5-Butyl-5-ethyl-1,3-diazinane-2,4,6-trione
|
|
| Clinical data | |
| Trade names | Soneryl |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration |
Oral |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Excretion | Renal |
| Identifiers | |
| CAS Number | 77-28-1  |
| ATC code | N05CA03 |
| PubChem | CID 6473 |
| DrugBank | DB01353 |
| ChemSpider | 6229 |
| UNII | OHZ8QAW6YC |
| KEGG | D02618 |
| ChEMBL | CHEMBL404422 |
| Chemical data | |
| Formula | C10H16N2O3 |
| Molar mass | 212.246 g/mol |
|
|
|
|
| (verify) | |
Butobarbital (BAN), also called butobarbitone or butethal, Soneryl, and Neonal,[1] is a hypnotic drug which is a barbiturate derivative. It was developed by Poulenc Brothers (now part of Rhône Poulenc) in 1921.[2]
References[edit]
- ^ International Drug Names
- ^ DE Patent 481129
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
